CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Paratek Pharmaceuticals Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Paratek Pharmaceuticals Inc
75 Park Plaza, 4Th Floor
Phone: (617) 807-6600p:617 807-6600 BOSTON, MA  02116  United States Fax: (617) 275-0039f:617 275-0039
This company ceased filing statements with the SEC on 10/2/2023.
On 9/21/2023, the Company was acquired by Resistance Acquisition, Inc., a Company jointly controlled by affiliates of Gurnet Point Capital, LLC and Novo Holdings A/S
This company is no longer actively traded on any major stock exchange.
Business Summary
Paratek Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its commercial product, NUZYRA (omadacycline), is a once-daily oral and intravenous antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia (CABP), and acute skin and skin structure infections (ABSSSI) caused by susceptible pathogens. Its other commercial product SEYSARA (sarecycline), is a once-daily oral therapy for the treatment of moderate to severe acne vulgaris. The Sarecycline is a narrow spectrum tetracycline designed specifically for dermatological use. It markets omadacycline in the United States as an empiric monotherapy in the indications of ABSSSI and CABP for patients that have both a known or suspected resistant pathogen and at least one significant comorbidity.
(Source: 10-K)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/202312/31/2022YesYes--Yes

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Executive Chairman of the Board Michael F.Bigham 65 6/25/2019 10/30/2014
President, Chief Commercial Officer AdamWoodrow 56 6/1/2019 10/1/2014
Chief Executive Officer, Director EvanLoh 64 6/25/2019 10/30/2014
7 additional Officers and Directors records available in full report.

Business Names
Business Name
Manchester Pharmaceuticals LLC
Paratek Ireland Limited
Paratek Pharma, LLC
8 additional Business Names available in full report.

General Information
Number of Employees: 268 (As of 2/28/2023)
Outstanding Shares: 57,322,358 (As of 7/31/2023)
Shareholders: 79
Stock Exchange: NASD
Federal Tax Id: 330960223
Fax Number: (617) 275-0039


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, April 17, 2024